Author

Zia Shariat-Madar

Unknown affiliation - Cited by 2,876

Biography

Zia Shariat Madar, PhD is in the School of Pharmacy at the University of Mississippi. He received his BS degree in Biology and MS degree in Public Health Education from Central Michigan University. He received his Ph.D in Pharmacology at the Medical University of Ohio and did postdoctoral work at the University of Michigan.
Title
Cited by
Year
Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis
GA LaRusch, F Mahdi, Z Shariat-Madar, G Adams, RG Sitrin, WM Zhang, ...Blood, The Journal of the American Society of Hematology 115 (24), 5111-5120, 2010201
122
2010
Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis
GN Adams, GA LaRusch, E Stavrou, Y Zhou, MT Nieman, GH Jacobs, ...Blood, The Journal of the American Society of Hematology 117 (14), 3929-3937, 2011201
100
2011
The anticancer potential of steroidal saponin, dioscin, isolated from wild yam (Dioscorea villosa) root extract in invasive human breast cancer cell line MDA-MB-231 in vitro
P Aumsuwan, SI Khan, IA Khan, Z Ali, B Avula, LA Walker, ...Archives of Biochemistry and Biophysics 1, 98-110, 2016201
59
2016
Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells
L Duan, N Motchoulski, B Danzer, I Davidovich, Z Shariat-Madar, ...Journal of Biological Chemistry 286 (4), 2864-2876, 2011201
39
2011
Plasma kallikrein inhibitors in cardiovascular disease
D Kolte, Z Shariat-MadarCardiology in Review 24 (3), 99-109, 2016201
36
2016
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
B Shariat-Madar, D Kolte, A Verlangieri, Z Shariat-MadarDiabetes, metabolic syndrome and obesity: targets and therapy, 67-78, 2010201
33
2010
Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase
SM Chajkowski, J Mallela, DE Watson, J Wang, CR McCurdy, JM Rimoldi, ...Biochemical and biophysical research communications 405 (3), 8-343, 2011201
33
2011
The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT
L Duan, G Ying, B Danzer, RE Perez, Z Shariat-Madar, VV Levenson, ...Journal of Biological Chemistry 289 (31), 21694-21705, 2014201
29
2014
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2
GA LaRusch, A Merkulova, F Mahdi, Z Shariat-Madar, RG Sitrin, DB Cines, ...American Journal of Physiology-Heart and Circulatory Physiology 305 (3 …, 2013201
26
2013
Novel redox-responsive amphiphilic copolymer micelles for drug delivery: Synthesis and characterization
J Bae, A Maurya, Z Shariat-Madar, SN Murthy, S JoThe AAPS journal 17, 1357-1368, 2015201
26
2015
Free fatty acids: circulating contributors of metabolic syndrome
C Suiter, SK Singha, R Khalili, Z Shariat-MadarCardiovascular & Hematological Agents in Medicinal Chemistry (Formerly …, 2018201
24
2018
Pregnane steroidogenesis is altered by HIV-1 Tat and morphine: Physiological allopregnanolone is protective against neurotoxic and psychomotor effects
JJ Paris, P Liere, S Kim, F Mahdi, ME Buchanan, SR Nass, AN Qrareya, ...Neurobiology of stress 12, 100211, 2020202
22
2020
Biochemical characterization of a novel high‐affinity and specific plasma kallikrein inhibitor
D Kolte, JW Bryant, D Holsworth, J Wang, P Akbari, GW Gibson, ...British journal of pharmacology 162 (7), 1639-1649, 111
20
2011
Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor)
J Wang, A Matafonov, H Madkhali, F Mahdi, D Watson, AH Schmaier, ...Current molecular medicine 14 (9), 13-1185, 2014201
17
2014
High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells
D Kolte, N Osman, J Yang, Z Shariat-MadarJournal of Biological Chemistry 286 (28), 24561-24571, 2011201
17
2011
Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis
F M Rabey, R SVS Gadepalli, S Diano, Q Cheng, T Tabrizian, D Gailani, ...Current medicinal chemistry 19 (24), 4194-4206, 2012201
16
2012
Mechanism for neurotropic action of vorinostat, a pan histone deacetylase inhibitor
S Shukla, Z Shariat-Madar, LA Walker, BL TekwaniMolecular and Cellular Neuroscience 77, 11-20, 2016201
13
2016
PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis
D Kolte, J W Bryant, G W Gibson, J Wang, Z Shariat-MadarCardiovascular & Hematological Agents in Medicinal Chemistry (Formerly …, 202
12
2012
Prolylcarboxypeptidase gene expression in the heart and kidney: Effects of obesity and diabetes
T Tabrizian, F Hataway, D Murray, Z Shariat-MadarCardiovascular & Hematological Agents in Medicinal Chemistry (Formerly …, 2015201
11
2015
Physiological effects of the plasma kallikrein-kinin system: roles of the Blood Coagulation Factor XII (Hageman Factor)
J Lynch, Z Shariat-MadarJournal of Clinical Toxicology 2 (3), 1-3, 2012201
6
2012

Referred From: https://scholar.google.com/citations?user=OeSBOjgAAAAJ&hl=en

Cited by
Citations 2876
h-index 29
i10-index 46
Recommended Journals
Open Access Journals